Neumora Therapeutics, Inc. (NMRA) insider trading

By person

16 insiders · 76 transactions

16.8×

Paul L. Berns holds 16.8 times base salary in stock. $11.80M of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Paul L. Berns last reported holding, valued at $1.60, the price Common Stock was last bought or sold at on the open market here, on 21 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

ARCH Venture Partners X, LLC entity

10% owner

$56.00M (3)

—

+$56.00M

6,046,907

3.22%

$9.65M

—

Kristina Burow

Director

$36.43M (20)

—

+$36.43M

6,094,624

3.24%

$9.73M

—

Amgen Inc entity

10% owner

$30.00M (1)

—

+$30.00M

35,368,653

18.82%

$56.44M

—

ARCH Venture Partners XII, LLC entity

10% owner

$10.93M (19)

—

+$10.93M

6,046,907

3.22%

$9.65M

+246.6%

Joshua Pinto

President & CEO

—

$1.20M (6) scheduled

−$1.20M

209,950

0.1117%

$335.04K

−56.1%

Robert A. Lenz

Head of R&D

—

$1.09M (6) scheduled

−$1.09M

309,092

0.1645%

$493.25K

—

Daljit Singh Aurora

See Remarks

—

$1.04M (14) scheduled

−$1.04M

48,750

0.0259%

$77.80K

−78.7%

Matthew K Fust

Director

—

$370.96K (2) scheduled

−$370.96K

20,100

0.0107%

$32.08K

—

Henry O Gosebruch

President & CEO

$189.37K (1)

—

+$189.37K

477,345

0.2540%

$761.75K

+24.8%

Paul L Berns

See Remarks

—

$57.93K (2)

−$57.93K

7,395,185

3.94%

$11.80M

−3.3%

Michael Lee Milligan

See Remarks

—

$8.47K (2) scheduled

−$8.47K

21,034

0.0112%

$33.57K

+450.2%

Carol Y. Suh

Chief Operating Officer

—

374,674

0.1994%

$597.90K

+29.3%

Fmr LLC entity

See Remark 1

—

88,289

0.0470%

$140.89K

—

Maykin Ho

Director

—

20,100

0.0107%

$32.08K

—

David Piacquad

Director

—

20,100

0.0107%

$32.08K

—

Alaa Halawa

Director

—

20,100

0.0107%

$32.08K

—

Neumora Therapeutics, Inc.

What the insiders did Net buying

By person